A study recently published in the Journal of Alzheimer’s Disease gives hope in the search of Alzheimer’s disease (AD) biomarkers indicating that some complement factors such as clusterin may serve as reliable predictors of Alzheimer’s disease progression.
The recognition that inflammation is an important player in Alzheimer’s disease and likely an early event in disease pathogenesis brings to the fore the potential use of markers of inflammation. Non–specific indicators of peripheral inflammation such as C–reactive protein and inflammatory cytokines have proved unreliable as markers of disease or disease progression, suggesting that a more targeted approach, focussing on specific inflammatory pathways might be more rewarding.
It is well known that inflammation and pro-inflammatory mediators contribute to the pathogenesis of dementia and Alzheimer’s. The complement system, part of the innate immunity and a potent driver of inflammation, “enhances (complements) the ability of antibodies and phagocytic cells to clear microbes and damaged cells”.
Previous research also implicates this innate immune system in the development of Alzheimer’s disease. Several published studies have explored whether plasma levels of complement components, regulators or activation products are altered in AD or predict progression in the disease. Inone of the first untargeted proteomics analyses of plasmain AD,complement factor H (FH)wasfoundto be elevated in ADplasmacompared to controls.
In the Journal of Alzheimer’s Disease study, Svetlana Hakobyan and colleagues from Cardiff University, King’s College London and University of Oxford, UK, used acustom–madeten–analytemultiplex set on the MSD platform to measureselectedcandidateAD biomarkercomplement proteinsand activation products.The setcomprised FH (measured as the individual Y402 and H402 alleles ),clusterin, FI, C1s, C9, C4d, Bb, iC3b, TCC.The four complement activation products selected for measurement included markers of classical (C4d, iC3b), alternative (Bb, iC3b) and terminal (terminal complement complex; TCC) pathwayactivation.
The authors compared samples from individuals with Alzheimer’s and healthy matched controls. The authors also studied samples from individuals with mild cognitive impairment (MCI) who had subsequently converted to dementia, when re-assessed 12 months later (convertors), or who had remained stable over the period of assessment (non-convertors). The researchers also designed a multiplex assay to measure simultaneously ten complement analytes.
The investigators demonstrated that clusterin alone among the analytes tested differentiated AD patients from matched controls, while clusterin, FI and TCC were all significantly different between MCI convertors and non–convertorsat one year post–sampling.In the sample set authors used, 26% of the MCI cases progressed to dementia at one year; this is markedly higher than published annual conversion rates, typically around 10%, although considerable variation between sample sets has been noted.
Association ofplasmaclusterin levels with rate of cognitive decline has been reported both in MCI andAD in eachof thesestudies, higher clusterin levels predicted more rapid decline. The results reported in this study demonstrating substantially higher plasma clusterin in MCI convertors compared to non–convertors robustly support these findings and show that elevated plasma clusterin is a powerful predictor of progression.
The study provides further evidence that complement proteins may contribute to disease progression in Alzheimer’s, and that combinations of complement biomarkers can aid diagnosis, patient stratification and prediction of outcome in MCI and Alzheimer’s disease.
Professor Paul Morgan, the senior author of the study, and director of Cardiff University’s Systems Immunity Research Institute, stated “We hope to build on this in order to develop a simple blood test that can predict the likelihood of developing Alzheimer’s disease in older people with mild, and possibly innocent, memory impairment.”